SOLARIS Peripheral PMCF Trial

Inclusion Criteria: * Corresponding to the IFU indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions. * Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator) * Patient presenting a score from 2 to 5 following Rutherford classification * Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study * Patient is \>18 years old * Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * The target lesion is either a modified TASC-II class A, B, C or D lesion. * The target lesion has angiographic evidence of stenosis or restenosis \> 50% or occlusion which can be passed with standard guidewire manipulation * There is angiographic evidence of a patent Common and Deep Femoral Artery Exclusion Criteria: * PTA is technically not possible (not feasible to access the lesion or a defect with the guidewire or balloon catheter) * Presence of an aneurysm immediately adjacent to the site of stent implantation * Stenosis distal to the site of stent implantation * Lesions in or adjacent to essential collaterals(s) * Lesions in locations subject to external compression * Heavily calcified lesions resistant to PTA * Patients with diffuse distal disease resulting in poor stent outflow * Patients with a history of coagulation disorders * Patients with aspirin allergy or bleeding complications and patients unable or unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to anticoagulant/antiplatelet therapy * Fresh thrombus formation * Patients with known hypersensitivity to the stent material (L605) and/or PTFE * The target lesion is either a modified TASC-II class B or D lesion with aortic or common femoral lesion involvement. * Previously implanted stent(s) at the same lesion site * Reference segment diameter is not suitable for the available stent design * Untreatable lesion located at the distal outflow arteries * Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure * Patients refusing treatment * Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated * Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site * Perforation at the angioplasty site evidenced by extravasation of contrast medium * Patients with a history of prior life-threatening contrast medium reaction * Patients with uncorrected bleeding disorders * Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding * Life expectancy of less than twelve months * Any planned surgical intervention/procedure within 30 days of the study procedure * Any patient considered to be hemodynamically unstable at onset of procedure * Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.